Kazia Therapeutics Limited (ASX:KZA – Get Rating) insider Bryce Carmine purchased 135,000 shares of the firm’s stock in a transaction on Monday, March 13th. The stock was bought at an average cost of A$0.12 ($0.08) per share, with a total value of A$16,200.00 ($10,872.48). Bryce Carmine also recently made the following trade(s): On Friday, March […]
Kazia Therapeutics Limited (ASX:KZA – Get Rating) insider Steven Coffey purchased 135,000 shares of the firm’s stock in a transaction that occurred on Monday, March 20th. The stock was purchased at an average price of A$0.12 ($0.08) per share, with a total value of A$16,200.00 ($10,872.48). Kazia Therapeutics Price Performance The company has a debt-to-equity […]
Kazia says its future success will be measured by commercialisation milestones after the company recorded its maiden revenue in the 2021 financial year.
The DFCI study (NCT04906096) is an open-label phase II clinical trial of paxalisib in PCNSL and is expected to recruit up to 25 patients and up to two.